Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004).
OBJECTIVE-To assess survival time in dogs that underwent treatment for stage III osteosarcoma and evaluate factors affecting survival. DESIGN-Retrospective case series. ANIMALS-90 dogs with stage III osteosarcoma. PROCEDURES-Records in the osteosarcoma database at the Animal Cancer Center at Colorado State University from 1985 to 2004 were searched for dogs with metastatic disease at the time of evaluation. Dogs were included in the study if they had metastasis to any site and if treatment was initiated. A Kaplan-Meier survival analysis was performed, and the influences of age, sex, breed, primary tumor site, metastatic sites, and treatment on outcome were analyzed via log-rank analysis. RESULTS-Median survival time was 76 days, with a range of 0 to 1,583 days. No significant differences in survival times on the basis of age, sex, breed, or primary site were observed. Breeds and primary tumor sites were typical of those usually associated with osteosarcoma in dogs. Dogs treated palliatively with radiation therapy and chemotherapy had a significantly longer survival time (130 days) than dogs in all other treatment groups. Dogs treated with surgery alone had a significantly shorter survival time (3 days) than dogs treated with surgery and chemotherapy (78 days). Dogs with bone metastases had a longer survival time than dogs with soft tissue metastases. CONCLUSIONS AND CLINICAL RELEVANCE-Treatment of dogs with stage III osteosarcoma can result in various survival times. Dogs with metastasis to bone and dogs that were treated palliatively with radiation and chemotherapy had the longest survival times.
Boston
Sarah E
SE
Colorado State University Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Ehrhart
Nicole P
NP
Dernell
William S
WS
Lafferty
Mary
M
Withrow
Stephen J
SJ
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy / Q000662:veterinary*; D003120:Colorado / Q000453:epidemiology; D003131:Combined Modality Therapy; D004283:Dog Diseases / Q000401:mortality* / Q000601:surgery / Q000628:therapy; D004285:Dogs; D005260:Female; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging / Q000662:veterinary; D012516:Osteosarcoma / Q000401:mortality / Q000601:surgery / Q000628:therapy / Q000662:veterinary*; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
D000970:Antineoplastic Agents